Press Releases
Samsung Biologics wins Asia-Pacific Vaccine Excellence Award 2021 (AVEA 2021)
Samsung Biologics announced the winning of an award for the Best Vaccine CMO of the Year from Asia-Pacific Vaccine Excellence Award 2021(AVEA 2021), hosted by IMAPAC (Impactful Connections and Intelligence), a networking foundation that provides one-stop shop of market intelligence and business connections for biopharmaceutical professionals and businesses.
The Asia-Pacific Vaccine Excellence Awards aims to recognize Asia's vaccine manufacturers who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality, and safety in vaccine development and manufacturing. Samsung Biologics is currently in agreement with Moderna to provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine which was announced in May this year.
"It's an honor to receive this award and be recognized as a team for our efforts and capabilities to manufacture vaccines in a short time frame," said David King, Director of Drug Product Operations at Samsung Biologics. "Samsung Biologics has grown tremendously within the past decade and I would like to take this opportunity to thank all the teams and also the clients for the generous support they have shown us to successfully manage the manufacturing processes throughout."
Samsung Biologics announced the winning of an award for the Best Vaccine CMO of the Year from Asia-Pacific Vaccine Excellence Award 2021(AVEA 2021), hosted by IMAPAC (Impactful Connections and Intelligence), a networking foundation that provides one-stop shop of market intelligence and business connections for biopharmaceutical professionals and businesses.
The Asia-Pacific Vaccine Excellence Awards aims to recognize Asia's vaccine manufacturers who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality, and safety in vaccine development and manufacturing. Samsung Biologics is currently in agreement with Moderna to provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine which was announced in May this year.
"It's an honor to receive this award and be recognized as a team for our efforts and capabilities to manufacture vaccines in a short time frame," said David King, Director of Drug Product Operations at Samsung Biologics. "Samsung Biologics has grown tremendously within the past decade and I would like to take this opportunity to thank all the teams and also the clients for the generous support they have shown us to successfully manage the manufacturing processes throughout."